IDEAS home Printed from https://ideas.repec.org/a/spr/pharmo/v8y2024i6d10.1007_s41669-024-00518-2.html
   My bibliography  Save this article

Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain

Author

Listed:
  • Sergio Cedillo

    (AstraZeneca Farmacéutica Spain S.A.)

  • Almudena González-Domínguez

    (Weber)

  • Yoana Ivanova-Markova

    (Weber)

  • Rafael López López

    (Complejo Hospitalario de Santiago de Compostela)

  • Sara López-Tarruella Cobo

    (Universidad Complutense, Madrid, Spain)

  • José Alberto Peña Pedrosa

    (Hospital Clínico San Carlos)

Abstract

Objective Here we estimate the cost-effectiveness of olaparib in the Spanish National Health Service (SNHS) as adjuvant treatment of early germline mutations in the BRCA1/2 genes (gBRCAm) HER2-negative (HER2neg) breast cancer (BC) with high risk of recurrence. Methods A semi-Markov model was adapted to the Spanish healthcare setting, using the perspective of the SNHS, and a lifetime horizon. Two scenarios were compared: receiving olaparib versus standard of care (SoC) treatment. The model comprised five health states and included the clinical results of the OlympiA trial, along with the direct healthcare costs associated with the use of early BC and subsequent treatment resources (€2023). A discount rate of 3% was applied for future cost and quality-of-life outcomes. A probabilistic sensitivity analysis (PSA) was carried out. Results The introduction of olaparib as adjuvant treatment for patients with early gBRCAm HER2neg BC with high risk of recurrence could involve an incremental cost of €44,273 and €50,164, with an improvement of 1.14 and 1.28 quality-adjusted life years (QALYs) for hormone receptor-positive (HR+) and triple-negative (TN) patients, respectively. Therefore, adjuvant olaparib could be cost-effective for early gBRCAm HER2neg BC, with an incremental cost-effectiveness ratio of €38,839/QALY and €39,084/QALY for HR+ and TN patients, respectively. The results from the PSA showed that 75.7% and 82.2% of the simulations fell below the €60,000/QALY threshold. Conclusions Olaparib as adjuvant treatment could be cost-effective in gBRCAm patients with early HER2neg BC in Spain.

Suggested Citation

  • Sergio Cedillo & Almudena González-Domínguez & Yoana Ivanova-Markova & Rafael López López & Sara López-Tarruella Cobo & José Alberto Peña Pedrosa, 2024. "Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain," PharmacoEconomics - Open, Springer, vol. 8(6), pages 887-896, November.
  • Handle: RePEc:spr:pharmo:v:8:y:2024:i:6:d:10.1007_s41669-024-00518-2
    DOI: 10.1007/s41669-024-00518-2
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s41669-024-00518-2
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1007/s41669-024-00518-2?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:8:y:2024:i:6:d:10.1007_s41669-024-00518-2. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.